Study of gecacitinib plus pegylated interferon for polycythemia vera
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of two drugs—gecacitinib (a JAK inhibitor) and pegylated interferon—to see if they work better together for people with polycythemia vera (PV), a blood cancer that causes too many red blood cells. The study is for patients who have not tried these specific treatments before and who have symptoms like high blood counts, weight loss, night sweats, or an enlarged spleen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with polycythemia vera (PV) by standard criteria.
- You have at least one of these: high blood counts (HCT ≥45%, platelets >400, or white blood cells ≥10), significant weight loss, night sweats, itching, unexplained fever, worsening spleen enlargement, or a past blood clot or bleed.
- You have not been treated with pegylated interferon or a JAK inhibitor (like ruxolitinib) before.
- Your major organs (liver, kidneys) are working well, and your blood counts are stable.
- You are able to swallow pills and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new pill, flonoltinib, for people with polycythemia vera whose blood counts are hard to control and who have not responded well to or couldn't tolerate current treatments. The goal is to see if the pill can lower the number of red blood cells and reduce symptoms, potentially reducing the need for frequent blood removal procedures.
This study tests an experimental pill called PRT12396 for people with myeloproliferative neoplasms (MPN). It aims to see if the drug is safe and helps control the disease.
This study tests a new oral drug (ZE74-0282) for people with blood cancers that have a specific genetic change called JAK2 V617F. The goal is to see if the drug is safe and helps control the cancer.
This Phase 2 trial tests a combination of pegylated interferon and ruxolitinib in adults with polycythemia vera who can’t tolerate hydroxyurea or don’t respond well to it. If you qualify, it may help control blood counts and disease symptoms when standard treatment hasn’t worked.
This trial tests a new drug, gecacitinib, for patients with moderate to severe chronic graft-versus-host disease (cGVHD) that has not improved after 2 to 5 prior treatments. It aims to see if the drug is safe and effective.
This study tests an injection called BEBT-507 for people with polycythemia vera (a blood condition that makes too many red blood cells). It's for those who haven't responded well to or can't tolerate standard treatments like hydroxyurea or interferon. The goal is to see if this new drug can help control the disease.
Hear when a new Polycythemia Vera (PV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.